SHANGHAI, China I May 20, 2025 I Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology ...

Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with ...

Pending data from the Phase 1 trial, Oruka plans to initiate a Phase 2 study of ORKA-002 in moderate-to-severe psoriasis in the first half of 2026. The planned study design will evaluate the safety ...

BAY 3670549 is an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor with potential to help control ...

MUNICH, Germany I May 20, 2025 I Tubulis today announced that the first program from its strategic license agreement with Bristol Myers Squibb has entered ...

HENDERSON, NV, USA I May 20, 2025 I Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated ...

Olezarsen met the primary endpoint with a statistically significant mean reduction in triglycerides versus placebo at 80 mg and 50 mg doses – ...

VANCOUVER, Canada I May 19, 2025 I Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, ...

BOSTON, MA, USA I May 19, 2025 I Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...

GAITHERSBURG, MD, USA I May 19, 2025 I Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Clinical data of Cytora's oral mucosa stem cells treatment shown to be safe and may be efficient as a disease modifying therapy in moderate stages of Multiple ...

NEW YORK, NY, USA I May 19, 2025 I Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, ...